Literature DB >> 28712489

Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.

Alexander I Makarkov1, Sabrina Chierzi2, Stéphane Pillet3, Keith K Murai4, Nathalie Landry5, Brian J Ward6.   

Abstract

INTRODUCTION: Plant-made virus-like particles (VLP) bearing influenza virus hemagglutinins (HA) are novel vaccine candidates that induce cross-reactive humoral and poly-functional T cell responses. To better understand the mechanisms that underlie this broad immunogenicity we studied early interactions of VLPs bearing either H1 (A/California/07/2009 (H1N1)) or H5 (A/Indonesia/05/2005 (H5N1)) with a human monocytoid cell line (U-937 cells) and human monocyte-derived macrophages (MDMs) as model antigen-presenting cells (APC). METHODS AND
RESULTS: Using Vibrio cholerae sialidase and lectins that target α2,6- (Sambucus nigra lectin) or α2,3-linked sialic acids (Maackia amurensis lectin I), we demonstrated that VLPs bind to these APCs in a sialic acid-dependent manner. Using lysosomal markers and DiD-labelled VLPs, we found that attachment to the cell surface leads to internalization, trafficking to acidic cell compartments and fusion of the VLP lipid envelope with endosomal membranes. Incubation of MDMs with H1- but not H5-VLPs induced proliferation of autologous peripheral blood mononuclear cells suggesting antigen processing and stimulation of a memory T cell response.
CONCLUSIONS: Plant-made VLPs bearing influenza HA not only mimic the structure of influenza virions to some degree but also recapitulate key features of the initial virus-APC interaction. These observations may help to explain the balanced humoral and cellular responses to plant-made VLP vaccines.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human monocyte-derived macrophage; Immunogenicity; Influenza; Plant-made vaccine; U-937 cell line; Virus-like particle

Mesh:

Substances:

Year:  2017        PMID: 28712489     DOI: 10.1016/j.vaccine.2017.07.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

Authors:  Stéphane Pillet; Julie Couillard; Sonia Trépanier; Jean-François Poulin; Bader Yassine-Diab; Bruno Guy; Brian J Ward; Nathalie Landry
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

2.  A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities.

Authors:  Breanna Hodgins; Stephane Pillet; Nathalie Landry; Brian James Ward
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

3.  Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge.

Authors:  Breanna Hodgins; Stephane Pillet; Nathalie Landry; Brian J Ward
Journal:  Immun Ageing       Date:  2019-11-04       Impact factor: 6.400

4.  Effects of Receptor Specificity and Conformational Stability of Influenza A Virus Hemagglutinin on Infection and Activation of Different Cell Types in Human PBMCs.

Authors:  Jens Dorna; Andreas Kaufmann; Viktoria Bockmann; Hartmann Raifer; Johanna West; Mikhail Matrosovich; Stefan Bauer
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

Review 5.  Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.

Authors:  Peter Pushko; Irina Tretyakova
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

Review 6.  Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production.

Authors:  Elizabeth Monreal-Escalante; Abel Ramos-Vega; Carlos Angulo; Bernardo Bañuelos-Hernández
Journal:  Vaccines (Basel)       Date:  2022-01-10

Review 7.  Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases.

Authors:  Maria Lobato Gómez; Xin Huang; Derry Alvarez; Wenshu He; Can Baysal; Changfu Zhu; Victoria Armario-Najera; Amaya Blanco Perera; Pedro Cerda Bennasser; Andera Saba-Mayoral; Guillermo Sobrino-Mengual; Ashwin Vargheese; Rita Abranches; Isabel Alexandra Abreu; Shanmugaraj Balamurugan; Ralph Bock; Johannes F Buyel; Nicolau B da Cunha; Henry Daniell; Roland Faller; André Folgado; Iyappan Gowtham; Suvi T Häkkinen; Shashi Kumar; Sathish Kumar Ramalingam; Cristiano Lacorte; George P Lomonossoff; Ines M Luís; Julian K-C Ma; Karen A McDonald; Andre Murad; Somen Nandi; Barry O'Keefe; Kirsi-Marja Oksman-Caldentey; Subramanian Parthiban; Mathew J Paul; Daniel Ponndorf; Elibio Rech; Julio C M Rodrigues; Stephanie Ruf; Stefan Schillberg; Jennifer Schwestka; Priya S Shah; Rahul Singh; Eva Stoger; Richard M Twyman; Inchakalody P Varghese; Giovanni R Vianna; Gina Webster; Ruud H P Wilbers; Teresa Capell; Paul Christou
Journal:  Plant Biotechnol J       Date:  2021-07-19       Impact factor: 13.263

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.